Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
22,951.60
(
0.00%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
102.97
(
2.28%
)
Bitcoin
68,539.00
(
-0.39%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ciotera post# 205940

Friday, 11/11/2016 9:27:23 AM

Friday, November 11, 2016 9:27:23 AM

Post# of 257295

I still like GILD's triplet because it's simpler… Not to mention the single-pill advantage.

As we’ve previously discussed, Glecaprevir/Pibrentasvir may be converted to a single pill (instead of two identical FDCs) in a supplemental NDA filing. If so, the single-pill advantage of GILD’s SOF/VEL/VOX will be temporary. (I don’t think it’s a big deal in any case.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today